Medscape |
DPP-4 Inhibitors and Heart Failure in Diabetes: Be Vigilant
Medscape MELBOURNE, Australia — Patients with type 2 diabetes who are at high risk for or who already have heart failure should not be precluded from receiving dipeptidyl peptidase-4 (DPP-4) inhibitor glucose-lowering agents, said most experts at the World … |
Novel Targeted Therapies in CLL Might Expand Treatment Options – Medscape
Novel Targeted Therapies in CLL Might Expand Treatment OptionsMedscapeOther studies with the novel agent in CLL are underway, including a phase 2 monotherapy study in patients with relapsed CLL and 17p deletions and combination studies with rituximab o…
Oman Dry Dock conducts blood donation drive – Oman Daily Observer
|
Oman Dry Dock conducts blood donation drive
Oman Daily Observer A blood donation campaign was organised recently by Oman Dry Dock SAOC in cooperation with the Blood Bank Unit, Ministry of Health, to mark the Sultanate’s 43rd National Day celebrations. The drive took place at the company’s premises in Muscat and … |
Seattle Genetics Highlights ADCETRIS(R) (Brentuximab Vedotin) Phase 2 … – MarketWatch
Seattle Genetics Highlights ADCETRIS(R) (Brentuximab Vedotin) Phase 2 …MarketWatchThe phase 2 clinical trial presented at ASH has been expanded to include a treatment arm to assess the activity and tolerability of ADCETRIS in combination with Rituxan…
Emergent Bio (EBS) Issues Encouraging Update on TRU-016 Phase 1b in CLL … – StreetInsider.com (subscription)
Emergent Bio (EBS) Issues Encouraging Update on TRU-016 Phase 1b in CLL …StreetInsider.com (subscription)Emergent Biosolutions (NYSE: EBS) announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy o…
Major faith leaders in UK unite to encourage organ donation – Business Standard
Major faith leaders in UK unite to encourage organ donationBusiness StandardMajor faith leaders in the UK have united to launch a new action plan aimed at boosting organ donation rates among religious communities, especially among Asian and minority et…
Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in … – Wall Street Journal
|
Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in …
Wall Street Journal Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in people with previously untreated … |
Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in … – MarketWatch
|
Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in …
MarketWatch “Emergent is pleased with the data from Cohort 1 of this Phase 1b study that show the safety and activity of otlertuzumab in combination with rituximab,” said Scott C. Stromatt, M.D., senior vice president and chief medical officer, Emergent BioSolutions. |
Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in … – Business Wire (press release)
|
Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in …
Business Wire (press release) ROCKVILLE, Md.–(BUSINESS WIRE)–Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in … |
Antitope Enters Research Agreement with Annexon to Generate Novel … – Cabume – Cambridge technology news
|
Antitope Enters Research Agreement with Annexon to Generate Novel …
Cabume – Cambridge technology news Under the terms of the agreement Annexon will provide antibodies against specific components of the complement system and Antitope will use its Composite Human Antibody™ technology to generate a series of fully humanised antibodies devoid of T cell … Antitope, Annexon Collab on Treatment for Neurodegenerative DiseasesGenetic Engineering News |